International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice
- PMID: 12356095
International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice
Abstract
The Food and Drug Administration (FDA) is publishing a guidance entitled "Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance describes or provides recommendations concerning the selection of test procedures and the setting and justification of acceptance criteria for new chemical drug substances and new drug products produced from them. The guidance is intended to assist in the establishment of a single set of global specifications for new drug substances and new drug products.
Similar articles
-
International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.Fed Regist. 1999 Aug 18;64(159):44928-35. Fed Regist. 1999. PMID: 12356094
-
International Conference on Harmonisation; draft guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products--FDA. Notice.Fed Regist. 1998 Jun 9;63(110):31506-13. Fed Regist. 1998. PMID: 10180131
-
International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.Fed Regist. 2001 Jul 13;66(135):36791-2. Fed Regist. 2001. PMID: 12356097
-
International harmonisation of regulatory requirements.Rev Sci Tech. 2007 Aug;26(2):415-20. Rev Sci Tech. 2007. PMID: 17892161 Review.
-
Pharmaceutical excipient development: the need for preclinical guidance.Regul Toxicol Pharmacol. 2000 Oct;32(2):210-8. doi: 10.1006/rtph.2000.1421. Regul Toxicol Pharmacol. 2000. PMID: 11067777 Review.
Cited by
-
Design and development of Unani anti-inflammatory cream.J Ayurveda Integr Med. 2017 Jul-Sep;8(3):140-144. doi: 10.1016/j.jaim.2017.03.002. Epub 2017 Jun 29. J Ayurveda Integr Med. 2017. PMID: 28669703 Free PMC article.
-
Quantification of Oseltamivir Phosphate Enantiomeric Impurity by Chiral HPLC Method With the Aid of Solvent Extraction and Phosphate Salt-Out Method.Chirality. 2025 May;37(5):e70034. doi: 10.1002/chir.70034. Chirality. 2025. PMID: 40336217 Free PMC article.
-
Introduction and clearance of beta-glucan in the downstream processing of monoclonal antibodies.Biotechnol Prog. 2021 Jul;37(4):e3149. doi: 10.1002/btpr.3149. Epub 2021 Mar 31. Biotechnol Prog. 2021. PMID: 33743183 Free PMC article.
-
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines.Front Pharmacol. 2018 Sep 28;9:1079. doi: 10.3389/fphar.2018.01079. eCollection 2018. Front Pharmacol. 2018. PMID: 30364154 Free PMC article. Review.
-
Points to consider when establishing drug product specifications for parenteral microspheres.AAPS J. 2010 Mar;12(1):27-32. doi: 10.1208/s12248-009-9156-6. Epub 2009 Nov 17. AAPS J. 2010. PMID: 19921439 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources